<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158104">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01935193</url>
  </required_header>
  <id_info>
    <org_study_id>ASAR160</org_study_id>
    <nct_id>NCT01935193</nct_id>
  </id_info>
  <brief_title>Aspirin Resistance Reversibility in Diabetic Patients</brief_title>
  <acronym>ARRDM</acronym>
  <official_title>Impact of Different Pharmacological Formulations on Aspirin Resistance Reversibility in Diabetics Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera San Giovanni Battista</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera San Giovanni Battista</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is assessing the prevalence of aspirin resistance in a cohort of
      diabetic patients. Those found resistant has been undergone pharmacological tests using
      different drug formulations to investigate the reversibility of aspirin resistance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>platelets aggregation assessed by two tests (PFA100 and VerifyNow)</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>diabetic patients found aspirin resistant receive and infusion of 288 mg of lysine acetylsalicylate and they are tested again 24 h after the infusion to investigate if aspirin resistance have been reversed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>stability of aggregation state after the reversion of aspirin resistance using oral formulation of lysine acetylsalicylate</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Aspirin Resistance</condition>
  <arm_group>
    <arm_group_label>asa resistant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>asa resistant patients receive endovenous infusion of lysine acetylsalicylate 288 mg and if asa resistance has been reversed they have been prescribed oral soluble salt of lysine acetylsalicylate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lysine acetylsalicylate</intervention_name>
    <arm_group_label>asa resistant</arm_group_label>
    <other_name>Flectadol</other_name>
    <other_name>Cardirene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabete mellitus type 2

          -  asa since 30 days at least

          -  plts &gt;150000 and &lt;450000

        Exclusion Criteria:

          -  recent ACS (within 30 days)

          -  anticoagulant therapy

          -  haemorragic diathesis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marta Bisi, MD</last_name>
    <phone>+393476985414</phone>
    <email>martadoro@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Giovanni Battista Hospital</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Bisi, MD</last_name>
      <phone>+393476985414</phone>
      <email>martadoro@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 30, 2013</lastchanged_date>
  <firstreceived_date>August 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera San Giovanni Battista</investigator_affiliation>
    <investigator_full_name>Marta Bisi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>platelets aggregation</keyword>
  <keyword>asa resistance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Acetylsalicylic acid lysinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
